Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tina Gerbek has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Birthe Lykke Thomsen

    Department of Pediatrics and Adolescent Medicine University Hospital of Copenhagen Copenhagen Denmark

    1 shared publication
  • Ena Muhic

    Department of Pediatrics and Adolescent Medicine University Hospital of Copenhagen Copenhagen Denmark

    1 shared publication
  • Jacob Nersting

    Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark

    1 shared publication
  • Kaspar Sørensen

    Department of Pediatrics and Adolescent Medicine University Hospital of Copenhagen Copenhagen Denmark

    1 shared publication
  • Kjeld Schmiegelow

    Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Copenhagen, Denmark

    1 shared publication
  • Klaus Kofoed

    Department of Cardiology, The Heart Center, Rigshospitalet University of Copenhagen Copenhagen Denmark

    1 shared publication

Latest Publications

  • Open Access

    Metabolic syndrome as a late effect of childhood hematopoietic stem cell transplantation – A thorough statistical evaluation of putative risk factors

    by Tina Gerbek, Birthe Lykke Thomsen, Ena Muhic, Terkel Christiansen, Kaspar Sørensen, Marianne Ifversen, Klaus Kofoed, Klaus Müller

    Background: Metabolic syndrome (MetS) is frequent among survivors of childhood hematopoietic stem‐cell transplantation (HSCT), but assessment of risk factors is challenged by survivor and participation bias in long‐term follow‐up studies.Methods: A cohort of 395 pediatric patients transplanted between 1980 and 2018 was investigated. MetS was assessed at follow‐up between December 2018 and March 2020. Two composite outcomes ((a) combining MetS and death, (b) combining MetS, death, and nonparticipation) were considered to address the risk of selection bias.Results: Among 234 survivors invited to the follow‐up, 96 individuals (median age 27 years) participated. MetS prevalence was 30% among participants. The only significant HSCT risk factor was a variable combining HSCT indication and conditioning with total‐body irradiation (TBI) (p = .0011). Compared to acute leukemias (AL) treated with high‐grade TBI (8–12 Gy), a lower MetS prevalence was seen for nonmalignant diseases treated with no/low‐grade TBI (0–4.5 Gy) (OR = 0.04, 95% confidence interval (CI): 0.00–0.23). Analyses of the composite outcomes indicated overestimation of the effect of high‐grade TBI due to selection bias. Scrutiny showed strong residual confounding between HSCT indication and high‐grade TBI within AL‐patients. The HSCT effect on MetS reflected HSCT effects on high‐density‐lipoprotein (HDL) and triglycerides. Compared to AL treated with high‐grade TBI, nonmalignant diagnoses treated with no/low‐grade TBI had higher HDL (+40%, 95% CI: +21% to +62%) and lower triglyceride (−59%, 95% CI: −71% to −42%).Conclusion: The TBI effect on MetS may be overestimated in follow‐up studies due to selection bias and confounding. The TBI effect was confined to the potentially modifiable MetS criteria HDL and triglyceride.


  • Role of TPMT and ITPA variants in mercaptopurine disposition

    by Tina Gerbek, Maria Ebbesen, Jacob Nersting, Thomas L. Frandsen, Malin Lindqvist Appell, Kjeld Schmiegelow

    To explore the levels of thioguanine incorporated into DNA (DNA-TG), and erythrocyte levels of 6-thioguanine nucleotides (Ery-TGN) and methylated metabolites (Ery-MeMP) during 6-mercaptopurine (6MP)/Methotrexate (MTX) therapy of childhood acute lymphoblastic leukemia (ALL) and the relation to inosine triphosphatase (ITPA) and thiopurine methyltransferase (TPMT) gene variants.